Effect of DEC drug in the treatment of allergic rhinitis patients.
- Conditions
- Health Condition 1: D80-D89- Certain disorders involving the immune mechanism
- Registration Number
- CTRI/2022/11/047741
- Lead Sponsor
- Prem Davis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Age: >18 years
2. Symptoms of Allergic Rhinitis â?? two or more symptoms of anterior or posterior rhinorrhea, Sneezing, nasal blockage, itching, watering of eyes, nasal and pharyngeal itching during two or more consecutive days for more than one hour on most days.
3. Patients not on any antiallergic medications and DEC for the past 2 weeks.
Exclusion Criteria
1. Pregnant Women
2. K/C/O Diabetes Mellitus with Random Blood Sugar values of >200mg/dl with oral and injectable antidiabetic drugs.
3. Allergic Fungal Rhinosinusitis
4. Past History of Nasal Surgery
5. Immunocompromised Patients (Patient with History of frequent infection, immunosuppressant therapy, history of chemo or radiotherapy)
6. Tumors of nose and paranasal Sinuses.
7. Hypersensitivity to Diethylcarbamazine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method